Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Collaborators:
Eli Lilly and Company
Daiichi Sankyo Inc.
Allies in Cardiovascular Trials Initiatives and Organized Networks:ACTION
Accumetrics, Inc.
Stentys
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01538446
First received: February 20, 2012
Last updated: January 17, 2014
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)